The global GLP-1 Agonists Weight Loss Drugs Market was valued at USD 13.8 billion in 2024 and is projected to grow from USD 27.5 billion in 2026 to USD 48.8 billion by 2030, registering a CAGR of 18.5% from 2025 to 2030. North America dominated the market with a 75.5% revenue share in 2024, supported by high obesity prevalence, favorable reimbursement policies, strong pharmaceutical...